Virchow Healthcare Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Virchow Healthcare Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $975.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Virchow Healthcare Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $975.6K Trade | TransData Nexus

Virchow Healthcare Private Limited

Indian Pharmaceutical Exporter · Other Specialist · $975.6K Total Trade · DGFT Verified

Virchow Healthcare Private Limited is an Indian pharmaceutical exporter with a total trade value of $975.6K across 2 products in 2 therapeutic categories. Based on 22 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Immunoglobulin ($900.0K), Device ($75.6K), .

Virchow Healthcare Private Limited — Export Portfolio & Destination Treemap

Virchow Healthcare Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Virchow Healthcare Private Limited? — Company Overview & Market Position

Virchow Healthcare Private Limited (VHPL) is a privately held pharmaceutical company established on November 20, 2007, in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24230MH2007PTC176048. VHPL operates as a subsidiary within the Virchow Group, a conglomerate with over 30 years of experience in the pharmaceutical industry. The group boasts an annual turnover exceeding $1 billion and employs over 5,000 individuals across its various entities.

VHPL's authorized and paid-up capital stands at ₹2.00 crore (approximately $250,000 USD). The company employs a dedicated team of professionals, with a focus on delivering advanced biological and pharmaceutical formulations to emerging markets. Its product portfolio includes advanced wound care, orthopedics, anti-thrombotics, oncology, blood and plasma products, anti-retrovirals, cardio-diabetics, probiotics, ophthalmics, cephalosporins, and nutraceuticals.

What Does Virchow Healthcare Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Immunoglobulin$900.0K 2

Product Portfolio — Top 2 by Export Value

Virchow Healthcare Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Immunoglobulin	Other	$900.0K	18	0.5%	11
2	Device	Medical Devices & Diagnostics	$75.6K	4	0.3%	13

Virchow Healthcare Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $975.6K. The top category is Other (92.3% of portfolio), followed by Medical Devices & Diagnostics (7.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Virchow Healthcare Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

VHPL operates manufacturing facilities within the Virchow Group, which encompasses 11 manufacturing sites. These facilities are strategically located to serve both domestic and international markets. The group's manufacturing capabilities include the production of critical high-purity active pharmaceutical ingredients (APIs) and intermediates, with Virchow Labs being recognized as the world's largest producer of Sulfamethoxazole and Trimethoprim.

3Key Leadership

The leadership team at VHPL comprises:

Kamal Kishore Ved Prakash Babbar: Managing Director, appointed on November 20, 2007.

Narayana Reddy Mundla: Director, appointed on November 20, 2007.

Hemanth Nandigala: Director, appointed on November 20, 2007.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Virchow Healthcare Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

VHPL has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's regulatory affairs team is equipped to work in synergy with both marketing and manufacturing teams, ensuring compliance with international standards. This includes processes from product selection to post-launch activities, with a focus on staying abreast of current and upcoming regulatory trends.

2Emerging Markets

VHPL has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's regulatory approvals include WHO-GMP, PIC/S (Ukraine), PPB (Kenya), NAFDAC (Nigeria), NDA (Uganda), and FDA (Ghana), facilitating access to these regions.

3Geographic Strategy

VHPL's geographic strategy involves diversification across multiple regions, including South-East Asia, Africa, Russia – CIS, and Latin & South America. This approach mitigates concentration risk and aligns with the company's strategic direction to provide affordable healthcare solutions globally.

Virchow Healthcare Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

VHPL's regulatory affairs team is equipped to work in synergy with both marketing and manufacturing teams, ensuring compliance with international standards. This includes processes from product selection to post-launch activities, with a focus on staying abreast of current and upcoming regulatory trends.

2WHO & EU GMP

VHPL has obtained WHO-GMP certification, facilitating access to various international markets. The company's regulatory affairs team ensures compliance with international standards, including WHO-GMP, to meet the stringent requirements of global markets.

3CDSCO & Indian Regulatory

VHPL holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained necessary approvals from state drug controllers. The company also possesses export No Objection Certificates (NOCs), enabling it to export pharmaceutical products to various international markets.

Virchow Healthcare Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

VHPL operates in a competitive landscape with several key players in the pharmaceutical industry. The company's focus on emerging markets and its diverse product portfolio, including advanced wound care, orthopedics, and oncology, position it favorably against competitors. VHPL's commitment to quality and regulatory compliance further strengthens its competitive edge.

2Key Differentiators

VHPL's key differentiators include its extensive product portfolio covering various therapeutic segments, a strong presence in over 50 countries, and a commitment to meeting stringent regulatory standards. The company's affiliation with the Virchow Group, a conglomerate with over 30 years of experience and an annual turnover exceeding $1 billion, provides additional strength and credibility.

3Strategic Position

VHPL's current strategic direction focuses on expanding its presence in emerging markets, diversifying its product offerings, and maintaining high-quality standards. The company's future outlook includes leveraging its regulatory approvals and manufacturing capabilities to enhance its position in the global pharmaceutical market.

Buyer Due Diligence Brief — Evaluating Virchow Healthcare Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

VHPL has demonstrated a consistent track record in pharmaceutical manufacturing, with a focus on quality and regulatory compliance. The company's export volume and consistency are supported by its regulatory approvals and strategic partnerships, indicating reliability in meeting international standards.

2Certifications to Verify

Importers should verify the following certifications when considering VHPL as a supplier:

WHO-GMP Certification: Ensures compliance with World Health Organization Good Manufacturing Practices.

EU GMP Certification: Confirms adherence to European Union Good Manufacturing Practices.

FDA Approval: Indicates compliance with U.S. Food and Drug Administration standards.

Frequently Asked Questions — Virchow Healthcare Private Limited

How many pharmaceutical products does Virchow Healthcare Private Limited export from India?

Virchow Healthcare Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Immunoglobulin ($900.0K), Device ($75.6K). Total export value is $975.6K.

What is Virchow Healthcare Private Limited's total pharmaceutical export value?

Virchow Healthcare Private Limited's total pharmaceutical export value is $975.6K, based on 22 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Virchow Healthcare Private Limited cover?

Virchow Healthcare Private Limited exports across 2 therapeutic categories. The largest are Other (92.3%, 1 products), Medical Devices & Diagnostics (7.7%, 1 products).

Get Full Virchow Healthcare Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.